MR Imaging of IDH Mutational Status in Brain Tumors

脑肿瘤 IDH 突变状态的 MR 成像

• 批准号: 8299794
• 负责人: Sabrina Miriam Ronen
• 金额: $ 20.16万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-02 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8299794
• 关键词: Acute Myelocytic Leukemia; Address; Biological Markers; Biopsy; Biopsy Specimen; Brain Neoplasms; Caring; Cells; Citric Acid Cycle; Clinical; Colon Carcinoma; Complex; Decarboxylation; Detection; Development; Disease; Enzymes; Event; Genotype; Glioblastoma; Glioma; Goals; Image; Isocitrate Dehydrogenase; Isocitrates; Knowledge; Magic; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of prostate; Mediating; Metabolic Diseases; Methods; Mitochondria; Molecular; Monitor; Motivation; Mutation; Outcome; Patient Care; Patients; Pattern; Phenotype; Quality of life; Regimen; Reporting; Research; Resolution; Risk; Stratification; Testing; Therapeutic; alpha ketoglutarate; base; cancer type; imaging modality; in vivo; innovation; isocitrate; molecular imaging; mutant; novel; novel therapeutic intervention; outcome forecast; prevent; tool; tumor; tumorigenesis

DESCRIPTION (provided by applicant): The goal of this project is to develop a hyperpolarized 13C magnetic resonance spectroscopy (MRS)- based approach for noninvasive assessment of the mutational status and activity of isocitrate dehydrogenase (IDH) by detecting synthesis of the oncometabolite 2-hydroxyglutarate (2-HG), which is produced by mutant IDH. Motivation: Mutations in IDH enzymes were recently reported in over 70% of low grade gliomas and secondary glioblastomas (GBM) as well as in 23% of acute myeloid leukemia patients and some cases of colon and prostate cancer. Whereas wild type IDH catalyzes the oxidative decarboxylation of isocitrate to ¿- ketoglutarate (alpha-KG), mutant IDH catalyzes the conversion of alpha-KG into 2-HG. Because 2-HG is likely involved in mediating oncogenesis, preventing its accumulation by inhibiting mutant IDH was proposed as a novel therapeutic approach. Noninvasive imaging of IDH mutational status and activity is critical for development and clinical implementation of such a therapy. Furthermore, when considering currently available therapies, the presence of 2-HG in GBM is associated with a group of patients that has better outcomes and benefits from less aggressive treatment. Imaging IDH status would thus serve to stratify GBM patients into molecular subtypes and optimize their treatment. To date, IDH mutations and 2-HG accumulation have only been detected by highly invasive methods involving extraction and analysis of biopsy samples. Using high-resolution magic angle spinning 1H MRS, 2-HG was recently detected in glioma patient biopsies. However, detection of 2-HG by 1H MRS in vivo remains a challenge, due to the complex spectral pattern of 2-HG and its overlap with neighboring metabolites. Noninvasive imaging biomarkers that inform on the mutational status of IDH are therefore needed for patient stratification and implementation of disease-appropriate treatments. Hypothesis: We hypothesize that the mutational status of IDH can be monitored by probing the conversion of alpha-KG into 2-HG using hyperpolarized 13C MRS. We will test this hypothesis through the following aims: Aim 1. To validate hyperpolarized [1-13C]-alpha-KG as a molecular imaging agent for monitoring mutant IDH activity using 13C MRS in cells. We will use 13C MRS and hyperpolarized [1-13C]-alpha-KG to monitor conversion of alpha-KG into 2-HG in wild type and mutant IDH cells. Aim 2. To validate the approach developed in Aim 1 as a method for determining IDH status in orthotopic brain tumors in vivo. We will investigate wild type and mutant IDH orthotopic brain tumors to confirm the value of the approach developed in Aim 1 for in vivo studies. PUBLIC HEALTH RELEVANCE: The proposed research will address the currently unmet need for a noninvasive imaging method to monitor the newly identified, cancer-associated, IDH mutation, which catalyzes the synthesis of the novel oncometabolite 2-HG. This type of innovative imaging will provide a tool to help optimize therapeutic regimens that are specifically tailored to the tumor genotype and result in more personalized care for patients harboring IDH mutations.

描述（由申请人提供）：该项目的目标是开发一种基于超极化13C磁共振波谱（MRS）的方法，通过检测突变IDH产生的肿瘤代谢物2-羟基戊二酸酯（2-HG）的合成，来无创评估异柠檬酸脱氢酶（IDH）的突变状态和活性。动机：IDH酶突变最近在超过70%的低级别胶质瘤和继发性胶质母细胞瘤（GBM）、23%的急性髓性白血病患者和一些结肠癌和前列腺癌病例中被报道。野生型IDH催化异柠檬酸盐氧化脱羧为α -酮戊二酸盐（α - kg），而突变型IDH催化α - kg转化为2-HG。由于2-HG可能参与介导肿瘤的发生，因此通过抑制突变型IDH来防止其积累被认为是一种新的治疗方法。IDH突变状态和活动的无创成像对于这种治疗的发展和临床实施至关重要。此外，考虑到目前可用的治疗方法，GBM中2-HG的存在与一组患者有更好的结果和从较低的积极治疗中获益相关。因此，IDH状态成像将有助于将GBM患者划分为分子亚型并优化其治疗。迄今为止，IDH突变和2-HG积累仅通过高侵入性方法检测到，包括提取和分析活检样本。利用高分辨率魔角旋转1H MRS，最近在胶质瘤患者活检中检测到2-HG。然而，由于2-HG的复杂光谱模式及其与邻近代谢物的重叠，用1H MRS检测体内2-HG仍然是一个挑战。因此，需要无创成像生物标志物来告知IDH的突变状态，以便对患者进行分层和实施适合疾病的治疗。假设：我们假设IDH的突变状态可以通过使用超极化13C mrs探测α - kg向2-HG的转化来监测。我们将通过以下目的来验证这一假设：验证超极化[1-13C]- α - kg作为分子显像剂，利用13C MRS在细胞中监测突变型IDH活性。我们将使用13C MRS和超极化[1-13C]- α - kg来监测野生型和突变型IDH细胞中α - kg向2-HG的转化。目标2。验证Aim 1中开发的方法作为一种在体内确定原位脑肿瘤中IDH状态的方法。我们将对野生型和突变型IDH原位脑肿瘤进行研究，以确认Aim 1中开发的方法在体内研究中的价值。